Analysts Getting More Bullish On ViroPharma Following Friday's 28+% Surge On Takeover Chatter

ViroPharma VPHM shares are up about three-quarters of a percent Monday morning on the heels of a 28-plus percent move higher on Friday. Traders in the name were responding to chatter the company had received offers from both Sanofi SNY and Shire SHPG. Monday morning numerous analysts are commenting and raising price targets on ViroPharma.

• Stifel Nicolaus raised target from $41 to $47, Buy rating maintained.
• Piper Jaffray target from $37 to $46, Overweight maintained.
• Oppenheimer target from $35 to $44, Outperform maintained.
• Mizuho sees value of $45 assuming cost savings if M&A does happen, believes could include a contingent value of $2-3/share related to cinryze.

ViroPharma shares last traded at $39.41.